title: [Effect of the Nucleus CMP forte in 46 patients with progressive spastic paraparesis. Randomized and blind study].
abstract: BACKGROUND
  Idiopatic or HTLV-1 associated progressive spastic paraparesis does not have a clear etiology or treatment.
  
  
  OBJECTIVE
  To assess the effects of a medication containing cytidinmonophosphate, uridintriphosphate and vitamin B 12 in the treatment of progressive spastic.
  
  
  METHODS
  Patients with the disease were randomly assigned to receive the Nucleus CMP forte (containing dysodic cytidinmonophosphate 5 mg, trisodic uridintriphosphate 3 mg and hydroxicobalamin 2 Mg) tid or placebo during six months. Gait, spasticity, degree of neurogenic bladder and somatosensitive evoked potentials were assessed during treatment.
  
  
  RESULTS
  Forty six patients aged 25 to 79 years old were studied, 24 were female and 29 HTLV-1 positive. Twenty two were treated with the drug and the rest with placebo. Gait and spasticity improved in 7 of 22 patients receiving the drug and 1 of 24 receiving placebo (p < 0.05). Neurogenic bladder improved in 10 of 22 receiving the drug and 4 of 24 receiving placebo (NS) Somatosensitive evoked potentials improved in four of seven patients treated with the drug and in two of seven treated with placebo.
  
  
  CONCLUSIONS
  The medication caused a modest improvement in patients with progressive spastic paraparesis and was free of side effects.
authors.affiliation: Departamento de Ciencias Neurológicas, Facultad de Medicina, Universidad de Chile (Campus Oriente), Hospital del Salvador, Santiago de Chile.
authors.forename: L
authors.initials: L
authors.lastname: Cartier
authors.forename: J L
authors.initials: JL
authors.lastname: Castillo
authors.forename: R
authors.initials: R
authors.lastname: Verdugo
mesh_terms: D000328:Adult; D000368:Aged; D003568:Cytidine Monophosphate / Q000494:pharmacology* / Q000627:therapeutic use*; D005073:Evoked Potentials, Somatosensory / Q000187:drug effects*; D005260:Female; D005684:Gait / Q000187:drug effects*; D006801:Humans; D006879:Hydroxocobalamin / Q000494:pharmacology* / Q000627:therapeutic use*; D008297:Male; D008875:Middle Aged; D009128:Muscle Spasticity / Q000188:drug therapy*; D015493:Paraparesis, Tropical Spastic / Q000503:physiopathology*; D014544:Uridine Triphosphate / Q000494:pharmacology* / Q000627:therapeutic use*; D001750:Urinary Bladder, Neurogenic / Q000188:drug therapy*
chemical_list: D003568:Cytidine Monophosphate; D006879:Hydroxocobalamin; D014544:Uridine Triphosphate